Peer-reviewed article
Timor-Leste's immunization journey: progress, challenges, and the road to IA2030 a viewpoint on leaving no child behind.
Mariano da Silva Marques, Filipe de Neri Machado, Noel Gama Soares, Nazario Barreto Dos Santos, Jimmi Bruno de Oliveira et al. ·
Summary
Written by AI, not yet AICS's view · claude-haiku-4-5-20251001Timor-Leste has made progress in its immunization program since 2000, reducing zero-dose children by 22% in one year and increasing government vaccine financing to 80%. However, measles vaccination coverage remains stuck at 72%, far below the 95% target needed for elimination, and surveillance systems for polio detection are weak. The country launched HPV vaccination for adolescent girls in 2024. Political commitment and targeted equity strategies have helped, but surveillance gaps and laboratory delays pose risks for disease outbreak detection.
Key points
- Zero-dose children decreased from 4,184 to 3,254 in one year (22% reduction)
- Districts with high DTP1-to-DTP3 dropout rates fell from 36% to 0%
- Government vaccine financing increased from 64% to 80% between 2022-2023
- MCV1 (measles) coverage stagnated at 72%, well below the 95% elimination threshold
- Non-polio AFP surveillance rate is 0.42/100,000, far below the global target of ≥2.0, and only 38% of IgM results returned within 4 days
Limitations
This is a viewpoint article that synthesizes secondary data from EPI fact sheets and reports rather than presenting primary research. It does not provide detailed epidemiological analysis or independent validation of the immunization coverage figures reported by the government.
Abstract
BACKGROUND: Timor-Leste, a post-conflict nation with a population of 1.34 million, has steadily developed its immunization program since 2000. This viewpoint analyzes progress toward the Immunization Agenda 2030 (IA2030) goals, identifies persistent surveillance gaps, and extracts lessons for other low-and middle-income countries. METHODS: We synthesized data from Timor-Leste's 2023 and 2024 EPI fact sheets, the July 2024 HPV vaccine launch report, WHO surveillance guidance, and IA2030 monitoring frameworks. Coverage trends (2014-2023) and surveillance indicators were evaluated against global standards. RESULTS: Zero-dose children reduced by 22% in one year (from 4,184 to 3,254). Districts with high dropout rates (DTP1 to DTP3) fell from 36% to 0%. Government financing for vaccines increased from 64% to 80% (2022-2023). However, MCV1 coverage stagnated at 72% (far below the 95% measles elimination threshold). The non-polio AFP rate (0.42/100,000) remains well below the global target of ≥2.0. Only 38% of IgM results returned within 4 days. HPV vaccine launched in July 2024, targeting 11-14-year-old girls. CONCLUSIONS: Timor-Leste demonstrates that political commitment and targeted equity strategies can reduce zero-dose children even in resource-constrained settings. However, surveillance system gaps, particularly for AFP and laboratory turnaround times, pose serious risks for polio eradication and outbreak detection. Key lessons for IA2030 implementation include the following: (1) political stability enables cumulative health system gains; (2) one-year indicator improvements require multi-year validation; (3) surveillance quality determines outbreak response speed; and (4) school-based platforms effectively reach adolescents.